Srx Health Solutions, Inc. · AMEX:SRXH
Srx Health Solutions — Investor Presentation (June 2025)
19 slides from Srx Health Solutions's investor presentation, June 2025
Slide 1: SRx Corporate Presentation
SRx Corporate Presentation June 2025 M a k i n g H e a l t h c a re S i m p l e
Slide 2: Forward Looking Statements
Forward Looking Statements The information in this presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements t o be covered by the safe harbor provisions for forward-looking statements contai
Slide 3: Leadership Team
Leadership Team Michael Young Adesh A. Vora Kent Cunningham Nina Martinez Board of Directors Founder & Chief Executive President Chief Financial Officer Officer Michael Young is a member of the Adesh Vora is the Founder and Chief Kent Cunningham is the P r e s i d e n t o f Nina Martinez is the Chie
Slide 4: A Lifelong Mission to Provide Quality Patient Care
A Lifelong Mission to Provide Quality Patient Care “After years in retail pharmacy, I felt that the system was broken and needed t o create a more patient-centric approach to support patients with chronic diseases.” Adesh Vora, Pharm. D. Founder & Executive Chairman SRx’s Start National Expansion SR
Slide 5: SRx At a Glance
SRx At a Glance What Are Specialty Pharmacies? Specialty pharmacies service patients with chronic diseases Deliver care and support that retail pharmacies cannot provide One Goal: Enhanced Patient Care *unaudited combined net revenue includes SRx nine-months ended June 30, 2024, and BTTR nine-months
Slide 6: Creating a North American Network
Creating a North American Network The SRx Network extends across Canada, making it one of the most accessible providers of specialty healthcare in the country. With 5 sites in Texas and licenses to distribute across 26 US states, the acquisition of Choice Specialty Pharmacy enhances SRx’s US presenc
Slide 7: SRx Ecosystem of Specialty Healthcare Services
SRx Ecosystem of Specialty Healthcare Services SRx’s specialty pharmacies serve as the foundation to the Company’s integrated network All-Inclusive Specialty Pharmacies Partner Engagement 20 pharmacies across Canada, providing Biologic Care Coordinators and Nurse Case personalized services. Capable
Slide 8: Complex Patient Care Ecosystem
Complex Patient Care Ecosystem The SRx network represents a critical link in facilitating specialty care Partner Physician Referral Patient referred t o SRx for specialty Patient Onboarding therapeutic treatment Introductory call, counseling, pre- screening and other administrative requirements Pre-
Slide 9: Strong Industry Tailwinds
Strong Industry Tailwinds Growing Prevalence of The Need for Specialty Market Attractiveness Chronic Disease in Seniors Pharmacists in Canada US specialty drug spend, Of Canadians aged 65+ 5 million Canadians are without 73% report having at least 1 access to a primary healthcare ~$410B represents a
Slide 10: Focus on Partnerships
Focus on Partnerships Continued YoY Expand Accelerate Physician Patient Support Expand Clinical Same Store Distribution Growth Partnerships Programs Trials Footprint Pharmacy Growth Capabilities Through M&A Continued Continued Developing Potential to To Service Pursuing high- same store relationship
Slide 11: Strategic Growth
Strategic Growth About Choice Specialty Pharmacy Growth Strategy Choice Specialty Pharmacy is a fully licensed Strengthens SRx’s specialty pharmacy provider of specialized pharmacy services in the footprint in t h e U.S., complementing U.S., dedicated t o delivering efficient, existing operations in
Slide 12: Summary Income Statement: Unaudited Pro Forma Combined
Summary Income Statement: Unaudited Pro Forma Combined (in thousands of USD) Better Choice SRx Accounting Adjustments Total Combined Nine Months Ended 9/30/2024 Nine Months Ended 6/30/2024 Net sales 27,817 117,109 144,926 Cost of sales 17,432 93,685 111,117 Gross profit 10,385 23,424 33,809 Operatin
Slide 13: Summary Balance Sheet: Unaudited Pro Forma Combined
Summary Balance Sheet: Unaudited Pro Forma Combined (in thousands of USD) Better Choice SRx Accounting Adjustments Total Combined As of 9/30/2024 As of 6/30/2024 Cash and cash equivalents 4,743 489 5,232 Total assets 17,172 64,002 (1,855)* 79,319 Total current liabilities 6,852 74,642 81,494 Total l
Slide 14: Pro Forma Capitalization Table
Pro Forma Capitalization Table Pro Forma Including Shares issued to SRx Health Solutions Shares Outstanding1 35,233,010 Ownership Options (WAEP: $105.44 ) 99,400 Non-Affiliates 25% Warrants (WAEP: $148.64 ) 269,345 Insiders 75%+ Fully Diluted 35,601,755 Shares Outstanding1 Combined Net Debt (USD)2 $
Slide 15: Investment Highlights
Investment Highlights Strong Industry Robust Strategic Rapidly Expanding Tailwinds Partnerships Healthcare Network 34 Specialty Health Clinics Prescribers 4 Clinical Trial Sites 20 Specialty Pharmacies Providers 400+ Dedicated Healthcare Professionals Leveraging Choice Specialty Pharmacy Acquisition
Slide 16: Slide 16
Slide 17: APPENDIX
APPENDIX
Slide 18: HALO OVERVIEW
HALO OVERVIEW Packed with nutrients. Minimally processed. Rich in flavor. For pet parents seeking all the Rooted in Nature benefits of a raw diet with the ease and convenience of freeze-dried raw food or snacks and treats Targeting most attractive consumer segments Designed for the pet parent seekin
Slide 19: Pro Forma Combined Debt Overview
Pro Forma Combined Debt Overview (As of September 30, 2024) Debt (USD millions) % Total Coupon PIK or Cash Interest Maturity Term Loan $33.9 86% 8.8% Cash Interest 2027 - In Forbearance Bank Indebtedness $3.6 9% Prime + 2.25% Cash Interest 2027 W intrust Receivables Credit Facility $1.9 5% Prime + 2
SRx Health Solutions — Investor Presentation (June 2025) on 6ix